Jackson Center, PA, August 18, 2020 – Halberd Corp. (OTC PINK: "HALB") Chairman, President & CEO of Halberd Corporation, William A. Hartman, has received a number of questions from shareholders regarding the extracorporeal process for treatment of Covid-19. Below, Mr. Hartman responds to those questions. Q: There are various extracorporeal medical procedures being researched or ...
Furthering the Fight Against Covid-19 Internationally Jackson Center, PA, August 10, 2020 – Halberd Corp. (OTC PINK: "HALB") today confirmed the addition of Dr. Abdon Nanhay as a member of the Scientific Advisory Board. Dr. Nanhay, a Brazilian physician, has over 25 years of experience in health and biological sciences. Dr. Nanhay’s experiences include general ...
Jackson Center, PA, August 4, 2020 – Halberd Corp. (OTC PINK: "HALB") announced today that they have secured non-dilutive, grant-based funding for their patent pending Covid-19 treatment(s). Newly formed Nonprofit Organization, Epidemiologic Solutions Corporation, a Louisiana, Internal Revenue Code Section 501(c)(3) application pending, has committed to provide funding of approximately $2,000,000, as required by Halberd ...
Will Assist with Covid-19 Efforts and the Brain Jackson Center, PA, July 27, 2020 – Halberd Corp. (OTC PINK: "HALB") announced the appointment of Carl Eller, retired NFL Pro Football Hall of Famer, and President of the NFL Retired Players Association as a consultant. Mr. Eller’s expertise and contacts will be leveraged as part of ...
Jackson Center, PA, July 22, 2020 – Halberd Corporation (OTC Pink: HALB) announced their Chief Technical Officer and Head of Scientific Advisory Board, Dr. Patricio Reyes, presented A Community Information Session virtual event hosted yesterday by the Brain Injury Alliance of Arizona, on “Covid-19 & the Nervous System; Neurological Complications That Can Result”. Dr. Reyes ...
Jackson Center, PA, July 16, 2020 – Halberd Corp. (OTC PINK: "HALB") intends to use laser technology to eradicate the COVID-19 Coronavirus. This patent pending treatment introduces one or more fluorescent antibody-antigen complexing agents to bind with the target antigen(s) (i.e., Covid-19 target antigens). This will allow the virus to be seen and located, and ...
Jackson Center, PA, July 13, 2020 – Halberd Corp. (OTC PINK: "HALB") today issued a statement to clarify certain items within its charter regarding allowable debt. There have been inaccurate rumors that have put the company in a negative light. One of these is that the company intends to take on convertible debt. Nothing could ...
Jackson Center, PA, July 7, 2020 – Halberd Corp. (OTC PINK: "HALB") today explains the second of three (3) COVID -19 (Coronavirus) patent pending treatments - “Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 Patients” - which was filed with the U.S. Patent and Trademark Office on ...
Jackson Center, PA, July 1, 2020 – Halberd Corporation (OTC-PINK: "HALB") announced the establishment of a subsidiary in the United Kingdom to facilitate access to European research facilities and markets. The subsidiary is Halberd Corporation UK, Ltd. William A. Hartman, Chairman, President & CEO of Halberd, stated, “This is the first step in our overall ...
Jackson Center, PA, June 29, 2020 – Halberd Corporation (OTC-PINK: "HALB") today unveils the first of three (3) COVID -19 (Coronavirus) patent pending treatment methods -- the first titled, “Method for Treating and Curing Covid-19 Infection” -- filed with the U.S. Patent and Trademark Office on March 16, 2020. Halberd holds exclusive worldwide license to ...